Studies find that there is a significant overlap in GO terms and KEGG pathways between Astragaloside IV targets and SARS-CoV-2 DEGs, included MMP13, NLRP3, TRIM21, GBP1, ADORA2A, PTAFR, TNF, MLNR, IL1B, NFKBIA, ADRB2, and IL6, which suggests that Astragaloside IV maybe a new drug candidate for alleviating hyper-inflammation in COVID-19 patients 27. This evidence concerns the gene NLRP3 and COVID-19.